CLINICAL TRIAL SUMMARY

MDACC Study No:2006-0375 (clinicaltrials.gov NCT No: NCT00866749)
Title:Augmented Berlin-Frankfurt-Munster therapy for adolescents/young adults with acute lymphoblastic leukemia or lymphoblastic lymphoma
Principal Investigator:Michael E. Rytting
Treatment Agent:6-MP; 6-Thioguanine; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Doxorubicin; Methotrexate; PEG-L-Asparaginase; Prednisone; Vincristine
Study Status:Open
Study Description:The goal of this clinical research study is to learn if augmented
Berlin-Frankfurt-Munster (BFM) will be an effective treatment for patients with
ALL or LL.

Hide details for General InformationGeneral Information

Disease Group:Leukemia; Lymphoma
Phase of Study:Phase II
Treatment Agents:6-MP
6-Thioguanine
Cyclophosphamide
Cytarabine
Daunorubicin
Dexamethasone
Doxorubicin
Methotrexate
PEG-L-Asparaginase
Prednisone
Vincristine
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston: 5 to 7days at the start of induction.
Supported By:N/A
Return Visit:weekly until maintenance therapy begins then monthly
Home Care:Home care as directed by the primary physician upon discussion with study
principal investigator


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Michael E. Rytting
Dept:Leukemia
For Clinical Trial Enrollment:713-792-4855
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults